CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 9,300,000 shares, a decline of 7.6% from the January 15th total of 10,070,000 shares. Based on an average trading volume of 1,710,000 shares, […]
Lifesci Capital Reiterates Outperform Rating for CymaBay Therapeutics (NASDAQ:CBAY) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) will release its earnings data after the market closes on Tuesday, November 7th. Analysts expect CymaBay Therapeutics to post earnings of ($0.30) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link. CymaBay Therapeutics (NASDAQ:CBAY – […]
HC Wainwright Increases CymaBay Therapeutics (NASDAQ:CBAY) Price Target to $19 00 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
StockNews.com downgraded shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) from a hold rating to a sell rating in a research note issued to investors on Wednesday. CBAY has been the subject of several other research reports. HC Wainwright increased their target price on CymaBay Therapeutics from $10.00 to $12.00 in a research report on […]